

Clearbridge's First Batch of Sinopharm Covid-19 Vaccine Arrives in Singapore; Providing More Vaccination Options for Those Unvaccinated

- *Clearbridge has procured the Sinopharm COVID-19 Vaccine directly from the manufacturer*
- *The Company's subsidiary operates a clinic, Medic Surgical & Laser Clinic, that has obtained the relevant approvals to import and administer the Sinopharm COVID-19 Vaccine in Singapore to patients under its care*
- *Sinopharm COVID-19 Vaccine is available at Medic Surgical & Laser Clinic, 1 Tanjong Pagar Plaza, #01-28, Singapore 082001 and registration for the Sinopharm COVID-19 Vaccine can be found here: <https://www.medicsurg.com/covid-19-vaccine/>*

SINGAPORE, 28 August 2021 – Asia's integrated healthcare company, **Clearbridge Health Limited** ("Clearbridge" or the "Company" and together with its subsidiaries, the "Group") ("明策集团"), is pleased to announce that its subsidiary, Clearbridge Medical Group Pte. Ltd. ("CBMG"), has received the first batch of SARS-CoV-2 Vaccine (Vero Cell), Inactivated or COVID-19 Vaccine (Vero Cell), Inactivated, also known as COVID-19 Vaccine BIBP (the "Sinopharm COVID-19 Vaccine") in Singapore.

On 9 August 2021, Clearbridge announced that CBMG has entered into a purchase contract with, among others, China National Biotec Group Company Limited (中国生物技术股份有限公司) ("CNBG") and Beijing Institute of Biological Product Co., Ltd. (北京生物制品研究所有限责任公司), a subsidiary of CNBG, to purchase the Sinopharm COVID-19 Vaccine for use in Singapore.

Based on a World Health Organization ("WHO") COVID-19 Vaccine – Explainer Document¹ dated 24 May 2021 (the "WHO Explainer"), the Sinopharm COVID-19 Vaccine is a form of vaccine categorised as "inactivated vaccines" which is reported to stimulate the body's immune system without risk of causing disease. Once inactivated viruses are presented to the body's immune system, they stimulate the production of antibodies, which prepares the body to respond to future live SARS-CoV-2 infections. In addition, the WHO Explainer had also cited a result of a large multi-country phase 3 trial which has shown that two doses administered at an interval of 21 days had the efficacy of 79% against symptomatic SARS-CoV-2 infection 14 days or more after the second dose. The Sinopharm COVID-19 Vaccine does not guarantee full immunity against COVID-19.

¹ Source: <https://www.who.int/publications/m/item/sinopharm-vero-cell---inactivated-covid-19-vaccine>



The Sinopharm COVID-19 Vaccine has been authorised for conditional or emergency use in several countries including the People’s Republic of China, the United Arab Emirates, Malaysia, Thailand and Indonesia. It has also been listed by the WHO for emergency use.

Medic Surgical Private Limited, a subsidiary of the Company which operates Medic Surgical & Laser Clinic, has been granted approval under the Health Sciences Authority of Singapore's Special Access Route (“SAR”) scheme to import and supply the Sinopharm COVID-19 Vaccine in Singapore (the “SAR Approval”). The SAR Approval is valid for a period of six months from 6 July 2021, unless subsequently renewed.

Located at 1 Tanjong Pagar Plaza, #01-28, Singapore 082001, Medic Surgical & Laser Clinic’s contact number is (+65) 6223 3303, Whatsapp number is (+65) 8868 7699 and its operating hours are on Monday – Friday: 9:00am – 7:00pm and Saturday: 9:00am – 1:00pm.

– END –

Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd.

Media & Investor Contact:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

About Clearbridge Health Limited

(Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3)

Aligning with the emerging healthcare trends in Asia, Clearbridge Health Limited is a healthcare group that currently provides a broad base of healthcare solutions via 3 distinctive strategic business units, comprising healthcare systems, medical clinics/centres and the strategic medical technology investments, in nexus of high demand across Asia.

For more information, please visit us at www.clearbridgehealth.com.

This press release has been prepared by the Company and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalyst. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.